Skip to main content

Table 2 Characteristics of N. gonorrhoeae isolates with AZM-R and CROD identified in Guangzhou in 2009-2013

From: Azithromycin-resistant Neisseria gonorrhoeae isolates in Guangzhou, China (2009–2013): coevolution with decreased susceptibilities to ceftriaxone and genetic characteristics

 

AZM-LLR (n = 33)

AZM-MLR (n = 44)

 
 

Totalc

CROD

Totalc

CROD

 
 

n (%)

n (%)

n (%)

n (%)

P

Antimicrobial resistance

33 (100.0)

6 (18.2)

44 (100)

19 (43.2)

b < 0.05

23 S rRNA

 WT

32 (97.0)

5 (15.2)

38 (86.3)

13 (29.5)

a, b > 0.05

 C2611TS

1 (3.0)

1 (3.0)

1 (2.3)

1 (2.3)

 

 C2611TAll

0 (0.0)

0 (0.0)

5 (11.4)

5 (11.4)

 

mtrR

     

 Deletiona

     

  Yes

29 (87.9)

6 (18.2)

42 (95.5)

19 (43.3)

a > 0.05, b: ND

  No

4 (12.1)

0 (0.0)

2 (4.5)

0 (0.0)

 

 Mutations

     

  WTb

2 (6.1)

0 (0.0)

2 (4.5)

0 (0.0)

a, b > 0.05

  A39T

7 (21.2)

4 (12.1)

6 (13.6)

4 (9.1)

 

  G45D

8 (24.2)

1 (3.0)

5 (11.3)

2 (4.5)

 

  H105Y

16 (48.5)

1 (3.0)

26 (59.1)

11 (25.0)

 

  A39T/ F62L

0 (0.0)

0 (0.0)

1 (2.3)

0 (0.0)

 

  A40D/T86A

0 (0.0)

0 (0.0)

1 (2.3)

0 (0.0)

 

  A40D/T86A/H105Y

0 (0.0)

0 (0.0)

1 (2.3)

1 (2.3)

 

  D79N/T86A/H105Y

0 (0.0)

0 (0.0)

1 (2.3)

1 (2.3)

 

  T86A/ H105Y

0 (0.0)

0 (0.0)

1 (2.3)

0 (0.0)

 

Mutation patterns in PBP2

     

  II or XIV

3 (9.1)

0 (0.0)

4 (9.1)

0 (0.0)

a, b > 0.05

  V

6 (18.2)

1 (3.0)

8 (18.2)

3 (6.8)

 

  VII

0 (0.0)

0 (0.0)

1 (2.3)

0 (0.0)

 

  VIII

0 (0.0)

0 (0.0)

1 (2.3)

1 (2.3)

 

  XII

2 (6.1)

0 (0.0)

2 (4.6)

1 (2.3)

 

  XIII

2 (6.1)

0 (0.0)

0 (0.0)

0 (0.0)

 

  XVII

2 (6.1)

1 (3.0)

0 (0.0)

0 (0.0)

 

  XVIII

5 (15.2)

2 (6.1)

13 (29.4)

10 (22.6)

 

  XXI

7 (21.2)

1 (3.0)

8 (18.2)

3 (6.8)

 

  XXVII

4 (12.2)

0 (0.0)

6 (13.6)

1 (2.3)

 

  New 1d

1 (3.0)

0 (0.0)

0 (0.0)

0 (0.0)

 

  New 2d

1 (3.0)

1 (3.0)

0 (0.0)

0 (0.0)

 

  New 3d

0 (0.0)

0 (0.0)

1 (2.3)

0 (0.0)

 

23rRNA/mtrR/penA mutation patterns

     

  WT/A-;H105Y/XVIII

2 (6.1)

0 (0.0)

4 (9.1)

3 (6.8)

a, b > 0.05

  WT/A-;H105Y/V

6 (18.2)

1 (3.0)

6 (13.6)

3 (6.8)

 

  WT/A-;H105Y/XXI

2 (6.1)

0 (0.0)

6 (13.6)

2 (4.5)

 

  WT/A-;G45D/XXI

4 (12.1)

3 (9.1)

0 (0.0)

0 (0.0)

 

  WT/A-;A39T/XVIII

3 (9.1)

3 (9.1)

5 (11.4)

3 (6.8)

 

  C2611TAll/A-;H105Y/XVIII

0 (0.0)

0 (0.0)

2 (4.5)

2 (4.5)

 

  C2611TAll/A-;G45D/XXI

0 (0.0)

0 (0.0)

2 (4.5)

2 (4.5)

 

  Other patterns

16 (48.5)

2 (6.1)

17 (38.6)

2 (4.5)

 
  1. AZM azithromycin, CRO D decreased susceptibility to ceftriaxone, CRO S susceptible to ceftriaxone, C2611T S mutation C2611T in a single allele, C2611T All C2611T mutations in all four alleles, aAdenine (A) deletion in the 13-bp inverted repeat (5’-AAAAAGACTTTTT-3’) within the -35 to -10 positions of the mtrR promoter. bUsing mtrR from N. gonorrhoeae FA1090 as a template. cIncluding CROS and CROD; dNew polymorphism patterns of PBP2: New 1 (A501V, F504L, A510V, A516G, H541N, P552V, I556V, I566V), New 2 (F504L, A510V, A516G, Y554H), New 3 (A501V, F504L, A510V, A516G, H541N, I566V). a: the AZM-LLR isolates were compared to the AZM-MLR isolates; b: the combined AZM-LLR/CROD isolates were compared to the combined AZM-MLR/CROD isolates; ND not determined (because of a small number of isolates)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us